ClinicalTrials.gg

Program

amlitelimab

Also written as “Amlitelimab”, “KY1005” and “SAR445229”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Immune System Diseases · Celiac Disease · Alopecia Areata, led by Sanofi.

Furthest: phase 3, since Aug 5, 202219 company-led studies, 5 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi195 open or runningphase 3since Aug 5, 2022May 11, 2017Sep 30, 2027phase 3 · NCT06241118

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since May 11, 2017.

  1. Aug 5, 2022Phase 3 study in Dermatitis, AtopicNCT05492578 · 1,856 enrolled · United States, Argentina, Australia and more
  2. Mar 3, 2023Phase 2 study in Dermatitis, AtopicNCT05769777 · 999 enrolled · United States, Argentina, Australia and more
  3. Aug 23, 2023Phase 2 study in Dermatitis, AtopicNCT06015308 · 224 enrolled · United States, Canada
  4. Sep 5, 2023Phase 2 study in AsthmaNCT06033833 · 335 enrolled · United States, Argentina, Brazil and more
  5. Oct 31, 2023Phase 2 study in HidradenitisNCT06118099 · 90 enrolled · United States, Australia, Canada and more
  6. Nov 8, 2023Phase 3 study in Dermatitis, AtopicNCT06130566 · 601 enrolled · United States, Argentina, Australia and more
  7. Dec 13, 2023Phase 3 study in Dermatitis, AtopicNCT06181435 · 589 enrolled · United States, Argentina, Bulgaria and more
  8. Jan 16, 20242 phase 3 studies in Dermatitis, AtopicNCT06224348, NCT06241118
  9. May 6, 2024Phase 3 study in Dermatitis, AtopicNCT06407934 · 1,541 enrolled · United States, Argentina, Australia and more
  10. May 31, 2024Phase 2 study in Alopecia AreataNCT06444451 · 166 enrolled · United States, Argentina, Australia and more
  11. Aug 14, 2024Phase 2 study in Celiac DiseaseNCT06557772 · 229 enrolled · United States, Argentina, Australia and more
  12. Nov 11, 2024Phase 1 study in Dermatitis, AtopicNCT06686628 · 23 enrolled · Germany
  13. Aug 21, 2025Phase 1 study in Healthy VolunteersNCT07146750 · 212 enrolled · United States
  14. Oct 2, 2026Phase 2 study terminatedStudy stoppedNCT06033833 · “Sponsor decision; the decision is not related to any safety concern.”

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06241118
  2. Jan 22, 2029Primary completion: phase 3 study in Dermatitis, AtopicNCT05492578
  3. Jun 11, 2031Primary completion: phase 2 study in Dermatitis, AtopicNCT05769777

TargetBeta

TNFSF4 →read by rule
“Tumor necrosis factor ligand superfamily member 4 inhibitor”ChEMBL 37, by rule

Other programs on TNFSF4

ProgramCompanyFurthest phaseStudies
brivekimigSanofiphase 26

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07146750Healthy Volunteers · United States1CompletedApr 8, 2026212
NCT06686628Dermatitis, Atopic · Germany1CompletedNov 21, 202523
NCT06557772Celiac Disease · United States, Argentina, Australia and more2Active, not recruitingAug 5, 2026229
NCT06444451Alopecia Areata · United States, Argentina, Australia and more2TerminatedSep 24, 2025166
NCT06407934Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingJun 10, 20261,541
NCT06241118Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingSep 30, 2027464
NCT06224348Dermatitis, Atopic · United States, Argentina, Brazil and more3CompletedAug 21, 2025643
NCT06181435Dermatitis, Atopic · United States, Argentina, Bulgaria and more3CompletedNov 25, 2025589
NCT06130566Dermatitis, Atopic · United States, Argentina, Australia and more3CompletedJul 23, 2025601
NCT06118099Hidradenitis · United States, Australia, Canada and more2TerminatedFeb 6, 202590
NCT06033833Asthma · United States, Argentina, Brazil and more2TerminatedSep 22, 2026335
NCT06015308Dermatitis, Atopic · United States, Canada2CompletedOct 1, 2025224
NCT05769777Dermatitis, Atopic · United States, Argentina, Australia and more2Active, not recruitingJun 11, 2031999
NCT05492578Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingJan 22, 20291,856
NCT05421598Asthma · United States, Argentina, Brazil and more2CompletedOct 11, 2024437
NCT05131477Eczema · United States, Australia, Bulgaria and more2CompletedApr 26, 2023390
NCT04449939Immune System Diseases · United Kingdom1CompletedNov 30, 202024
NCT03754309Dermatitis, Atopic · Germany, Poland, Spain and more2CompletedMay 12, 202089
NCT03161288Immune System Diseases · Netherlands1CompletedMar 30, 201864

How it is read

Names in the registry

  • “Amlitelimab”, 15 entries
  • “KY1005”, 3 entries
  • “SAR445229”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.